Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy. Presentation Details Title    Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 rand ...